SCHEDULE 13G/A 0001491719 XXXXXXXX LIVE 6 Ordinary Shares, par value GBP 0.05 per share (the "Shares") 12/31/2025 0001479615 Silence Therapeutics plc G8128Y157 12 Hammersmith Grove London X0 W6 7AP Rule 13d-1(d) Lombard Odier Asset Management (USA) Corp DE 0 5935955 0 5935955 5935955 N 4.2 IA OO Silence Therapeutics plc 12 Hammersmith Grove, London, United Kingdom, W6 7AP This statement is filed by Lombard Odier Asset Management (USA) Corp (the "Investment Advisor"), with respect to ADSs (as defined in Item 4) held by 1798 Volantis Fund Ltd, 1798 UK Small Cap Best Ideas Fund Ltd and one or more managed accounts. The Investment Advisor serves as the investment advisor to each of the foregoing. The address of the principal business office of the Investment Advisor is 452 Fifth Avenue, 25th Floor, New York, NY 10018. The Investment Advisor is a corporation organized under the laws of the State of Delaware. Y As of the date requiring the filing of this statement, the Investment Advisor beneficially owns an aggregate of 5,935,955 Shares, inclusive of 1,978,650 American Depositary Shares ("ADSs"), each of which represents, and at the holder's option is convertible into, three Shares. The percentages used herein and in the rest of this Schedule 13G are calculated based upon 141,701,848 Shares issued and outstanding as of October 30, 2025, as reported by the Company in its Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025. 4.2 0 5,935,955 0 5,935,955 N Y Y Y Y Y Y Lombard Odier Asset Management (USA) Corp /s/ Elyse Strauss 02/09/2026